<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        32-171-00
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2000
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ANGIOTEC 10MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ENALAPRIL MALEATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        34.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1055]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Dallah Health Care Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09AA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><br />ANGIOTEC contains an active substance called Enalapril Maleate. This belongs to the group of medicines called ACE inhibitors (angiotensin<br />converting enzyme inhibitors).<br />ANGIOTEC is used:<br />□ To treat high blood pressure (hypertension).<br />□ To treat heart failure (weakening of heart function). It can lower the need to go to hospital and can help some patients live longer.<br />□ To prevent the signs of heart failure. The signs include: shortness of breath, tiredness after light physical activity such as walking, or swelling of the<br />ankles and feet.<br />This medicine works by widening your blood vessels. This lowers your blood pressure. The medicine usually starts to work within an hour, and the effect<br />lasts for at least 24 hours. Some people will require several weeks of treatment until the best effect on your blood pressure is seen.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take ANGIOTEC:<br />□ If you are allergic to Enalapril Maleate or any of the other ingredients of this medicine (listed in section 6).<br />□ If you have ever had an allergic reaction to a type of medicine similar to this medicine called an ACE inhibitor.<br />□ If you have ever had swelling of your face, lips, mouth, tongue or throat which caused difficulty in swallowing or breathing (angiooedema) when the<br />reason why was not known or it was inherited.<br />□ If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.<br />□ If you are more than 3 months pregnant. (It is also better to avoid ANGIOTEC in early pregnancy &ndash; see Pregnancy section).<br />Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine.<br />Take special care with ANGIOTEC:<br />Talk to your doctor or pharmacist before taking this medicine:<br />□ If you have a heart problem.<br />□ If you have a condition involving the blood vessels in the brain.<br />□ If you have a blood problem such as low or lack of white blood cells (neutropenia/agranulocytosis), low blood platelet count (thrombocytopenia) or a<br />decreased number of red blood cells (anaemia).<br />□ If you have a liver problem.<br />□ If you have a kidney problem (including kidney transplantation). These may lead to higher levels of potassium in your blood which can be serious.<br />Your doctor may need to adjust your dose of ANGIOTEC or monitor your blood level of potassium.<br />□ If you are having dialysis.<br />□ If you have been very sick (excessive vomiting) or had bad diarrhoea recently.<br />□ If you are on a salt-restricted diet, are taking potassium supplements, potassium- sparing agents, or potassium-containing salt substitutes.<br />□ If you are over 70 years of age.<br />□ If you have diabetes. You should monitor your blood for low blood glucose levels, especially during the first month of treatment. The level of potassium<br />in your blood can also be higher.<br />□ If you have ever had an allergic reaction with swelling of the face, lips, tongue or throat with difficulty in swallowing or breathing. You should be aware<br />that black patients are at increased risk of these types of reactions to ACE inhibitors.<br />□ If you have low blood pressure (you may notice this as faintness or dizziness, especially when standing).<br />□ If you have collagen vascular disease (e.g. lupus erthematosus, rheumatoid arthritis or scleroderma), are on therapy that suppresses your immune<br />system, are taking the drugs allopurinol or procainamide, or any combinations of these.<br />□ If you are taking an mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus: medicines used to treat certain types of cancer or to prevent the body&rsquo;s<br />immune system from rejecting a transplanted organ). You may be at increased risk for an allergic reaction called angioedema.<br />□ If you are taking any of the following medicines used to treat high blood pressure:<br />- An angiotensin II receptor blocker (ARB) (also known as sartans - for example valsartan, telmisartan, irbesartan, etc.), in particular if you have<br />diabetes-related kidney problems. - Aliskiren.<br />Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g., potassium) in your blood at regular intervals.<br />See also information under the heading &ldquo;Do not take ANGIOTEC.&rdquo;<br />You must tell your doctor if you think you are (or might become) pregnant. This medicine is not recommended in early pregnancy, and must not be taken<br />if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see Pregnancy section).<br />You should be aware that this medicine lowers the blood pressure in black patients less effectively than in non-black patients.<br />If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking this medicine.<br />If you are about to have a procedure<br />If you are about to have any of the following, tell your doctor that you are taking ANGIOTEC:<br />□ Any surgery or receive anaesthetics (even at the dentist).<br />□ A treatment to remove cholesterol from your blood called &#39;LDL apheresis&#39;.<br />□ A desensitisation treatment, to lower the effect of an allergy to bee or wasp stings.<br />If any of the above applies to you, talk to your doctor or dentist before the procedure.<br />Taking other medicines with ANGIOTEC:<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes herbal medicines. This is because<br />ANGIOTEC can affect the way some medicines work. Also some other medicines can affect the way ANGIOTEC works. Your doctor may need to<br />change your dose and/or to take other precautions.<br />In particular tell your doctor or pharmacist if you are taking any of the following medicines:<br />□ An angiotensin II receptor blocker (ARB) or aliskiren (see also information under the headings &ldquo;Do not take ANGIOTEC&rdquo; and &ldquo;Take special care with<br />ANGIOTEC&rdquo;).<br />□ Other medicines to lower blood pressure, such as beta-blockers, angiotensin receptor-blockers, water tablets (diuretics).<br />□ Medicines containing potassium (including dietary salt substitutes).<br />□ Medicines for diabetes (including oral antidiabetic medicines and insulin).<br />□ Lithium (a medicine used to treat a certain kind of depression).<br />□ Medicines for depression called &#39;tricyclic antidepressants&#39;.<br />□ Medicines for mental problems called &lsquo;antipsychotics&#39;.<br />□ Certain cough and cold medicines and weight reducing medicines which contain something called a &lsquo;sympathomimetic agent&#39;.<br />□ Certain pain or arthritis medicines including gold therapy.<br />□ An mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus; medicines used to treat certain types of cancer or to prevent the body&rsquo;s immune<br />system from rejecting a transplanted organ). See also information under the heading &ldquo;Take special care with ANGIOTEC&rdquo;.<br />□ Non-steroidal anti-inflammatory drugs, including COX-2-inhibitors (medicines that reduce inflammation, and can be used to help relieve pain).<br />□ Aspirin (acetylsalicylic acid).<br />□ Medicines used to dissolve blood clots (thrombolytics).<br />□ Alcohol.<br />If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking ANGIOTEC.<br />Taking ANGIOTEC with food and drink:<br />ANGIOTEC can be taken with or without food. Most people take ANGIOTEC with a drink of water.<br />Pregnancy and breastfeeding:<br />Pregnancy:<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this<br />medicine. Your doctor will normally advise you to stop taking ANGIOTEC before you become pregnant or as soon as you know you are pregnant<br />and will advise you to take another medicine instead of ANGIOTEC. This medicine is not recommended in early pregnancy, and must not be taken<br />when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.<br />Breast-feeding:<br />Tell your doctor if you are breast-feeding or about to start breast-feeding. Breastfeeding newborn babies (first few weeks after birth), and especially<br />premature babies, is not recommended whilst taking this medicine. In the case of an older baby your doctor should advise you on the benefits and<br />risks of taking this medicine whilst breast-feeding, compared to other treatments.<br />Driving and using machines:<br />You may feel dizzy or sleepy while taking this medicine. If this happens, do not drive or use any tools or machines.<br />Important information about some of the ingredients of ANGIOTEC:<br />ANGIOTEC contains lactose, which is a type of sugar. If you have been told by your doctor that you have intolerance to some sugars, talk to your<br />doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<br />□ It is very important to continue taking this medicine for as long as your doctor prescribes it.<br />□ Do not take more tablets than prescribed.<br />High Blood Pressure:<br />□ The usual starting dose ranges from 5 to 20 mg taken once a day.<br />□ Some patients may need a lower starting dose.<br />□ The usual long term dose is 20 mg taken once a day.<br />□ The maximal long term dose is 40 mg taken once a day.<br />Heart Failure:<br />□ The usual starting dose is 2.5 mg taken once a day.<br />□ Your doctor will raise this amount step by step until the dose that is right for you has been achieved.<br />□ The usual long term dose is 20 mg each day, taken in one or two doses.<br />□ The maximal long term dose is 40 mg each day, divided in two doses.<br />Patients with kidney problems<br />Your dose of medicine will be changed depending on how well your kidneys are working:<br />□ Moderate kidney problems - 5 mg to 10 mg each day<br />□ Severe kidney problems - 2.5 mg each day<br />□ If you are having dialysis - 2.5 mg each day. On days you are not having dialysis, your dose may be changed depending on how low your blood<br />pressure is.<br />Elderly patients<br />Your dose will be decided by your doctor and will be based on how well your kidneys are working.<br />Use in children<br />Experience in the use of ANGIOTEC in children with high blood pressure is limited. If the child can swallow tablets, the dose will be worked out<br />using the child&rsquo;s weight and blood pressure. The usual starting doses are:<br />□ Between 20 kg and 50 kg &ndash; 2.5 mg each day.<br />□ More than 50 kg &ndash; 5 mg each day.<br />The dose can be changed according to the needs of the child:<br />□ A maximum of 20 mg daily can be used in children who are between 20 kg and 50 kg.<br />□ A maximum of 40 mg daily can be used in children who are more than 50 kg.<br />This medicine is not recommended in newborn babies (first few weeks after birth) and in children with kidney problems.<br />If you take more ANGIOTEC than you should:<br />If you take more ANGIOTEC than you should, talk to your doctor or go to a hospital straight away. Take the medicine pack with you. The following<br />effects may happen: feeling of light-headed or dizziness. This is due to a sudden or excessive drop in blood pressure.<br />If you forget to take ANGIOTEC:<br />□ If you forget to take a tablet, skip the missed dose.<br />□ Take the next dose as usual.<br />□ Do not take a double dose to make up for a forgotten dose.<br />If you stop taking ANGIOTEC:<br />Do not stop taking your medicine unless your doctor tells you to.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this<br />medicine:<br />Stop taking ANGIOTEC and talk to a doctor straight away, if you notice any of the following:<br />□ Swelling of your face, lips, tongue or throat which may cause difficulty in breathing or swallowing.<br />□ Swelling of your hands, feet or ankles.<br />□ If you develop a raised red skin rash (hives).<br />You should be aware that black patients are at increased risk of these types of reactions. If any of the above happen, stop taking ANGIOTEC and<br />talk to a doctor straight away.<br />When you start taking this medicine you may feel faint or dizzy. If this happens, it will help to lie down. This is caused by your blood pressure<br />lowering. It should improve as you continue to take the medicine. If you are worried, please talk to your doctor.<br />Other side effects include:<br />Very Common (may affect more than 1 in 10 people)<br />□ Feeling dizzy, weak or sick.<br />□ Blurred vision.<br />□ Cough.Common (may affect up to 1 in 10 people)<br />□ Light-headedness due to Low blood pressure, changes in heart rhythm, fast heartbeat, angina or chest pain.<br />□ Headache, depression, fainting (syncope), Change in sense of taste<br />□ Shortness of breath. □ Diarrhea or abdominal pain.<br />□ Tiredness (fatigue).<br />□ Rash, Allergic reactions with swelling of the face, lips, tongue or throat with difficulty in swallowing or breathing.<br />□ High levels of potassium in the blood, increased levels of creatinine in your blood (both are usually detected by a test).<br />Uncommon (may affect up to 1 in 100 people)<br />□ Flushing. □ Sudden fall in blood pressure. □ Fast or uneven heart beats (palpitations). □ Heart attack (possibly due to very low blood pressure<br />in certain high-risk patients, including those with blood flow problems of the heart or brain). □ Stroke (possibly due to very low blood pressure in<br />high-risk patients). □ Anaemia (including aplastic and haemolytic). □ Confusion, sleeplessness or sleepiness, nervousness. □ Feeling your skin<br />prickling or being numb. □ Vertigo (spinning sensation). □ Ringing in your ears (tinnitus). □ Runny nose, sore throat or hoarseness.<br />□ Asthma-associated tightness in chest. □ Slow movement of food through your intestine (ileus), inflammation of your pancreas. □ Being sick<br />(vomiting), indigestion, constipation, anorexia. □ Irritated stomach (gastric irritations), dry mouth, and ulcer. □ Muscle cramps.<br />□ Impaired kidney function, kidney failure. □ Increased sweating. □ Itching or nettle rash. □ Hair loss. □ Generally feeling unwell (malaise), high<br />temperature (fever). □ Impotence. □ High level of proteins in your urine (measured in a test). □ Low level of blood sugar or sodium, high level of<br />blood urea (all measured in a blood test).<br />Rare (may affect up to 1 in 1,000 people)<br />□ &lsquo;Raynaud&rsquo;s phenomenon&rsquo; where your hands and feet may become very cold and white due to low blood flow.<br />□ Changes in blood values such as a lower number of white and red blood cells, lower haemoglobin, lower number of blood platelets.<br />□ Bone marrow depression. □ Swollen glands in neck, armpit or groin. □ Autoimmune diseases. □ Strange dreams or sleep problems.<br />□ Accumulation of fluid or other substances in the lungs (as seen on X-rays). □ Inflammation of your nose. □ Inflammation of the lungs causing<br />difficulty breathing (pneumonia). □ Inflammation of the cheeks, gums, tongue, lips, throat. □ Reduced amount of urine.<br />□ Rash that looks like targets (erythema multiforme). □ &lsquo;Stevens-Johnson syndrome&rsquo; and &lsquo;toxic epidermal necrolysis&rsquo; (serious skin conditions<br />where you have reddening and scaling of your skin, blistering or raw sores), exfoliative dermatitis/erythroderma (severe skin rash with flaking or<br />peeling of the skin), pemphigus (small fluid-filled bumps on the skin).<br />□ Liver or gallbladder problems such as lower liver function, inflammation of your liver, jaundice (yellowing of the skin or eyes), high levels of liver<br />enzymes or bilirubin (measured in a blood test). □ Enlargement of breasts in males (gynaecomastia).<br />Very Rare (may affect up to 1 in 10,000 people)<br />□ Swelling in your intestine (intestinal angioedema).<br />Not known (frequency cannot be estimated from the available data)<br />□ Overproduction of antidiuretic hormone, which causes fluid retention, resulting in weakness, tiredness or confusion.<br />□ A symptom complex has been reported which may include some or all of the following: fever, inflammation of the blood vessels<br />(serositis/vasculitis), muscle pain (myalgia/myositis), joint pain (arthralgia/arthritis). Rash, photosensitivity or other skin manifestations may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>□ Keep out of the reach and sight of children.<br />□ Do not store above 30&deg;C.<br />□ Do not use ANGIOTEC after the expiry date which is stated on the carton and on the blister, after (EXP).Date.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required.<br />These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><br />□ The active substance is Enalapril Maleate. Each ANGIOTEC 5, 10, 20 tablets contains 5, 10 and 20 mg, of Enalapril Maleate, respectively.<br />□ The other ingredients are: lactose, maize starch and triglyceride stearic a</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ANGIOTEC 5 mg tablets are white, circular, flat face bevelled edge tablets with “AN 5” debossed on one side.
□ ANGIOTEC 10 mg tablets are white, circular, flat face bevelled edge tablet with “AN 10” debossed on one side.
□ ANGIOTEC 20 mg tablets are white, circular, flat face bevelled edge tablet with “AN 20” debossed on one side.
□ Boxes of 30 blistered tablets of ANGIOTEC 5 Tablets.
□ Boxes of 30 blistered tablets of ANGIOTEC 10 Tablets.
□ Boxes of 20 blistered tablets of ANGIOTEC 20 Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Jordanian pharmaceutical manufacturing co.(P.L.C.|)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>۱. ما هو أنجيوتك وما هي دواعي استعماله<br />يحتوي أنجيوتك على إنالابريل ماليات وهو المكوّن الفعال. وينتمي إلى مجموعة من الأدوية تعرف بمثبطات الإنزيم المحول للأنجيوتنسِين.<br />تستخدم أقراص أنجيوتك ل:<br />لعلاج ارتفاع ضغط الدم (الضغط). □<br />لعلاج قصور القلب (ضعف في وظيفة القلب)، ويمكن أن يقلل من الحاجة للذهاب إلى المستشفى ويمكن أن يساعد بعض المرضى على العيش لفترة أطول. □<br />لمنع ظهور علامات قصور القلب، والتي تشمل: ضيق في التنفس، التعب بعد النشاط البدني الخفيف مثل المشي، أو تورم في الكاحلين والقدمين. □<br />يعمل هذا الدواء على توسيع الأوعية الدموية، وبالتالي يساعد هذا التأثير على خفض ضغط الدم في الجسم.<br />عادةً يبدأ الدواء بالعمل في غضون ساعة، و يستمر تأثيره لمدة لا تقل عن ۲٤ ساعة. قد يحتاج بعض الأشخاص إلى عدة أسابيع من العلاج للحصول على أفضل تأثير من هذا الدواء<br />في خفض ضغط الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ذا كنت تعاني من حساسية لإنالابريل ماليات، أو لأي مادة أخرى موجودة في أقراص أنجيوتك (انظر القسم ٦: معلومات إضافية). □<br />إذا كنت قد عانيت من رد فعل تحسسي لنوع دواء مماثل لهذا الدواء والذي ينتمي إلى عائلة مثبطات الإنزيم المحول للأنجيوتنسِين . □<br />إذا كنت قد عانيت في أي وقت مضى من تورم في الوجه، الشفتين، الفم، اللسان أو الحلق الذي يسبب صعوبة في البلع أو التنفس (وذمة وعائية) ولم يكن السبب معروف أو كان □<br />السبب سبب وراثي.<br />إذا كان لديك مرض السكري أو ضعف في وظائف الكلى وكنت قد تعالجت بأدوية خافضة لضغط الدم و التي تحتوي على أليسكيرن. □<br />إذا كنت حاملاً لأكثر من ثلاث شهور، (و من الأفضل أيضاً تجنب أستخدام أنجيوتك في بداية الحمل &ndash; أنظري على قسم الحمل). □<br />لا تأخذ هذا الدواء إذا كان أي من هذه الموانع المذكورة أعلاه كانت تنطبق عليك، تحدث إلى طبيبك أو الصيدلاني إذا لم تكن متأكداً قبل تناول هذا الدواء.<br />الاحتياطات عند استعمال أنجيوتك:<br />تحدث إلى طبيبك أو الصيدلاني قبل تناول هذا الدواء.<br />إذا كان لديك مشاكل في القلب. □<br />إذا كان لديك حالة تشمل الأوعية الدموية في الدماغ. □<br />إذا كان لديك مشاكل في الدم مثل انخفاض أو نقص عدد خلايا الدم البيضاء (قلة العدلات/ ندرة المحببات)، أو انخفاض في عدد الصفائح الدموية (قلة الصفيحات) أو انخفاض في □<br />عدد خلايا الدم الحمراء (فقر الدم).<br />إذا كنت تعاني من مشاكل في الكبد. □<br />إذا كنت تعاني من مشاكل في الكلى (بما في ذلك عملية زرع الكلى). قد يؤدي هذا إلى ارتفاع مستويات البوتاسيوم في الدم و التي يمكن أن تكون خطيرة. قد يحتاج طبيبك إلى □<br />تعديل جرعة أنجيوتك أو مراقبة مستوى البوتاسيوم في الدم.<br />إذا كنت من المرضى الذين يقومون بعملية غسيل الكلى. □<br />إذا كان لديك غثيان شديد( قيء مفرط ) أو كان لديك إسهال سيء مؤخراً. □<br />إذا كنت تتبع نظام غذائي مقيد بالملح، وكنت تتناول مكملات البوتاسيوم، أو مدرات البول الموفرة للبُوتاسيوم ، أو بديل الملح الذي يحتوي على البوتاسيوم. □<br />إذا كان عمرك ۷۰ عاماً أو أكثر. □<br />إذا كنت تعاني من مرض السكري فإنه عليك مراقبة سكر الدم خوفاً من حدوث انخفاض في مستويات الجلوكوز في الدم خاصة خلال الشهر الأول من تلقي العلاج. يمكن لمستويات □<br />البوتاسيوم في الدم أن تكون مرتفعة أيضاً.<br />إذا كنت قد عانيت في أي وقت مضى من أي رد فعل تحسسي مع تورم في الوجه، الشفتين، اللسان أو الحلق و صعوبة في البلع أو التنفس، ويجب عليك أن تكون على علم بأن □<br />. ACE المرضى ذوات البشرة السوداء هم أكثر عرضة للأصابة بهذا النوع من التفاعلات من مثبطات<br />إذا كنت تعاني من انخفاض في ضغط الدم (قد تلاحظ هذا على شكل إغماء أو دوخة خصوصاً عند الوقوف). □<br />إذا كنت تعاني من أمراض الكولاجين الوعائية (ذئبة حمامية أو التهاب المفاصل الروماتويدي أو تصلب الجلد) أو كنت تستخدم العلاجات المثبطة للمناعة أو تتناول الأدوية التالية: □<br />الوبيورينول أو بروكيناميد أو أي تركيبات من هذه الأدوية.<br />على سبيل المثال: تيمسيروليموس، سيروليموس، إيفيروليموس: الأدوية المستخدمة لعلاج أنواع معينة من السرطان أو لمنع الجهاز المناعي ) mTOR إذا كنت تتناول مثبطات □<br />للجسم من رفض عضو مزروع). قد تكون في خطر متزايد للتعرض لرد فعل تحسسي يسمى الوذمة الوعائية.<br />المعروف أيضا باسم سارتانز - على سبيل المثال فالسارتان، ) II إذا كنت تأخذ أي من الأدوية التالية المستخدمة لعلاج ارتفاع ضغط الدم: - مضادات مستقبلات الأنجيوتينسن □<br />تلميسارتان، إربيسارتان، وما إلى ذلك)، لا سيما إذا كان لديك مشاكل الكلى المرتبطة بالسكري. - أليسيكرين.<br />قد يقوم طبيبك بفحص وظائف الكلى، وضغط الدم، وكمية الشوارد الكهربائية (مثل البوتاسيوم) في الدم على فترات منتظمة.<br />انظر أيضاً المعلومات تحت عنوان &quot;موانع استخدام أنجيوتك &quot;.<br />يجب عليك إخبار طبيبك إذا كنت تعتقدين أنك حاملاً (أو قد تصبحين). لا ينصح بهذا الدواء في وقت مبكر من الحمل، ويجب ألا يؤخذ إذا كنت حاملاً لمدة أكثر من ۳ أشهر، لأنه قد<br />يسبب ضرراً خطيراً لطفلك إذا استخدم في تلك المرحلة (انظر قسم الحمل).<br />يجب أن تكون على علم بأن أنجيوتك يعمل على خفض ضغط الدم عند المرضى ذوي البشرة السوداء بفعالية أقل مما هو عليه في المرضى أصحاب البشرة غير السوداء.<br />إذا لم تكن متأكداً إذا كان أياً مما أعلاه ينطبق عليك أو حدث معك سابقاً، تحدث إلى طبيبك أو الصيدلاني قبل تناول هذا الدواء.<br />إذا كنت على وشك البدء في الدواء<br />أخبر طبيبك بأنك تتناول أنجيوتيك:<br />إذا كنت على وشك القيام بأي بعملية جراحية أو تتلقى أحد الأدوية المخدرة (حتى عند طبيب الأسنان). □<br />إذا كنت على وشك البدء بعلاج إزالة الكولسترول من الدم (فصادة البروتين الشحمي خفيض الكثافة). □<br />إذا كنت على وشك أن تخضع لعلاج إزالة التحسس للحد من تفاعلات الحساسية اتجاه لسعات النحل أو الدبابير. □<br />إذا كان أي مما سبق ينطبق عليك، تحدث إلى طبيبك أو طبيب الأسنان قبل البدء بالعلاج.<br />تناول أنجيوتيك مع أدوية أخرى<br />قد تتغير فعالية دواء أنجيوتك إذا أخذ في نفس الوقت مع بعض الأدوية الأخرى . أخبر الطبيب أو الصيدلاني إذا كنت تأخذ أو أخذت مؤخراً أو قد تأخذ أي أدوية أخرى، بما في ذلك<br />الأدوية التي تم الحصول عليها من دون وصفة طبية ويشمل ذلك الأدوية العشبية، هذا لأن أنجيوتك يمكنه أن يؤثر على فاعلية بعض الأدوية. وأيضاً بعض الأدوية الأخرى يمكنها أن<br />تؤثر على عمل أنجيوتك، من الممكن أن يبدل طبيبك الجرعة و/أو يأخذ احتياطات أخرى.<br />تحدث إلى طبيبك أو الصيدلاني قبل تناولك أنجيوتك إذا كنت تتناول أحد الأدوية التالية:<br />أو أليسكيرن (انظر أيضاً المعلومات تحت عناوين &quot; موانع استعمال أنجيوتك&quot; و &quot; الاحتياطات عند استعمال لأنجيوتك &quot;). II مضادات مستقبلات الأنجيوتينسن □<br />الأدوية الأخرى الخافضة لضغط الدم، مثل حاصرات بيتا، حاصرات مستقبلات الأنجيوتنسين، مدرات البول. □<br />الأدوية التي تحتوي على البوتاسيوم (بما في ذلك بدائل الملح الغذائية). □<br />الأدوية التي تستخدم لعلاج مرض السكري (بما في ذلك الأدوية المضادة للسكري التي تأخذ عن طريق الفم والأنسولين). □<br />الليثيوم (دواء يستخدم لعلاج بعض أنواع الاكتئاب). □<br />أدوية الإكتئاب، و تسمى (مضادات الإكتئاب ثلاثية الحلقات). □<br />أدوية المشاكل العقلية والتي تسمى (مضادات الذهان). □<br />بعض أدوية السعال والبرد والأدوية التي تقلل من الوزن والتي تحتوي على ما يسمى &quot;عامل الودي&quot;. □<br />بعض أدوية آلام أو التهابات المفاصل بما في ذلك العلاج بالذهب. □<br />على سبيل المثال، تمسيروليموس، سيروليموس، إيفروليموس؛ وهي أدوية تستخدم لعلاج أنواع معينة من السرطان أو لمنع الجهاز المناعي للجسم من رفض ) mTOR مثبطات □<br />العضو المزروع). انظر أيضاً المعلومات تحت عنوان &quot;الاحتياطات عند استعمال أنجيوتك&quot;.<br />الأدوية المضادة للإلتهابات غيرالستيرويدية، بما في ذلك ( الأدوية التي تقلل الالتهابات، و يمكن أن تستخدم في المساعدة على تخفيف الألم). □<br />الأسبيرين (حمض أسيتيل ساليسيليك). □<br />الأدوية التي تذيب الجلطات الدموية (التخثر). □<br />الكحول. □<br />إذا لم تكن متأكداً إذا كان أي مما سبق ينطبق عليك، تحدث مع طبيبك أو الصيدلي قبل تناول أنجيوتيك.<br />تناول أنجيوتك مع الطعام و الشراب:<br />من الممكن تناول أنجيوتك مع الطعام أو بدونه. معظم المرضى يأخذون أنجيوتك مع كأس من الماء.<br />الحمل والرضاعة:<br />الحمل<br />إذا كنت حاملاً أو مرضعة، وإذا كنت تعتقدين أنك حامل أو تخططين للحمل، اطلبي من طبيبك المشورة قبل تناول هذا الدواء.<br />عادةً سينصحكِ الطبيب بالتوقف عن تناول أنجيوتك قبل أن تصبحي حاملاً أو في أقرب وقت تعرفين فيه أنك حامل. لا ينصح بهذا الدواء في الوقت المبكر من الحمل، ويجب ألا يؤخذ<br />بعد الثلاثة أشهر الأولى من الحمل لأنه قد يسبب ضرراً وخيماً لطفلك .<br />الإرضاع<br />أخبري طبيبك إذا كنت مرضعة أو على وشك أن البدء بالرضاعة الطبيعية. ولا ينصح بإرضاع الأطفال حديثي الولادة (الأسابيع الأولى بعد الولادة)، و خاصةً الرضع الخُدج أثناء<br />تناول هذا الدواء. في حال الأطفال الأكبر سناً يجب على الطبيب أن يبين الفوائد والمخاطر من تناول هذا الدواء أثناء الرضاعة الطبيعية، بالمقارنة مع العلاجات الأخرى.<br />قيادة السيارات واستعمال الآلات:<br />قد يجعلك أنجيوتك تشعر بالنعاس أو الدوار. إذا حدث لك ذلك فإنه يجب عليك عدم القيادة أو استخدام الآلات أو الأدوات.<br />معلومات هامة حول بعض مكونات أنجيوتك:<br />يحتوي هذا الدواء على اللاكتوز وهو نوع من أنواع السكر. فإذا أخبرك طبيبك أنك تعاني من عدم تحمل لبعض السكريات، فإنه يجب عليك استشارته قبل تناول الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>۳. طريقة استخدام أنجيوتك<br />دائماً تناول أنجيوتك بالضبط كما أخبرك طبيبك أو الصيدلاني. يجب عليك التحقق من طبيبك أو الصيدلاني إذا كنت غير متأكد.<br />من المهم جداً متابعة تناول هذا الدواء كما وصفه الطبيب لك. □<br />لا تأخذ أقراص أكثر من المحدد. □<br />ارتفاع ضغط الدم:<br />۲۰ ملغم مرة واحدة يومياً. - الجرعة الأولية المعتادة هي ٥ □<br />قد يحتاج بعض المرضى إلى جرعة أولية أقل من ذلك. □<br />الجرعة المعتادة على المدى الطويل هي ۲۰ ملغم مرة واحدة يومياً. □<br />الجرعة القصوى على المدى الطويل هي ٤۰ ملغم مرة واحدة يومياً. □<br />الفشل القلبي:<br />الجرعة الأولية المعتادة هي ۲٫٥ ملغم مرة واحدة يومياً. □<br />سوف يرفع طبيبك هذه الكمية خطوة بخطوة حتی يتم تحقيق الجرعة المناسبة لك. □<br />الجرعة المعتادة على المدى الطويل هي ۲۰ ملغم يومياً، تأخذ على جرعة أو جرعتين يومياً. □<br />الجرعة القصوى هي ٤۰ ملغم، تقسم إلى جرعتين يومياً. □<br />الأشخاص الذين يعانون من مشاكل في الكلى<br />سيتم تغيير جرعة الدواء اعتماداً على مدى عمل الكليتين:<br />مشاكل متوسطة في الكلى - ٥ ملغم إلى ۱۰ ملغم يومياً. □<br />مشاكل الكلى الشديدة - ۲٫٥ ملغم يومياً. □<br />إذا كنت تقوم بعملية غسيل الكلى - ۲٫٥ ملغم كل يوم. في الأيام التي لم يكن لديك فيها غسيل الكلى، قد تتغير الجرعة اعتماداً على مدى انخفاض ضغط الدم. □<br />المرضى كبار السن<br />سوف يقوم الطبيب بتحديد الجرعة المقررة لك اعتماداً على مدى سلامة وظائف الكلى لديك.<br />الأستخدام في الأطفال<br />الخبرة في استخدام أنجيوتيك في الأطفال الذين يعانون من ارتفاع ضغط الدم محدودة. إذا كان الطفل قادر على ابتلاع الأقراص، فإن الجرعة ستعتمد على وزن الطفل وضغط دمه.<br />جرعة البدء المعتادة هي:<br />بين ۲۰ كغم و ٥۰ كغم - ۲٫٥ ملغم يومياً. □<br />أكثر من ٥۰ كغم - ٥ ملغم كل يوم. □<br />الجرعة يمكن تغييرها وفقا لاحتياجات الطفل:<br />يمكن استخدام ۲۰ ملغم يومياً كحد أقصى في الأطفال الذين تتراوح أوزانهم بين ۲۰ كغم و ٥۰ كغم. □<br />يمكن استخدام ٤۰ ملغم يومياً كحد أقصى في الأطفال الذين يزيد وزنهم عن ٥۰ كغم. □<br />لا ينصح هذا الدواء في الأطفال حديثي الولادة (الأسابيع القليلة الأولى بعد الولادة) وفي الأطفال الذين يعانون من مشاكل في الكلى.<br />الجرعة الزائدة من أنجيوتك:<br />إذا تناولت أقراص أنجيوتك أكثر مما يجب، فإن عليك إخبار طبيبك أو الذهاب إلى المستشفى على الفور. قم بأخذ الأقراص معك، قد تعاني من الآثار التالية: الشعور بدوار بالرأس أو<br />دوخة. ويرجع ذلك إلى انخفاض مفاجئ أو مفرط في ضغط الدم.<br />نسيان تناول جرعة أنجيوتك:<br />إذا نسيت تناول القرص، تخطى عن الجرعة التي نسيتها. □<br />لا تقلق إذا نسيت تناول الجرعة. □<br />تناول جرعتك التالية في موعدها. □<br />لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. □<br />التوقف عن تناول أنجيوتك:<br />لا تتوقف أبداً عن تناول أقراص أنجيوتك إلا إذا أخبرك طبيبك بذلك.<br />اسأل طبيبك أو الصيدلاني إذا كانت لديك أي أسئلة أخرى حول استخدام المستحضر.<br />٤. الأعراض الجانبية<br />كغيره من الأدوية، أقراص أنجيوتك يمكن أن تسبب آثار جانبية، وإن لم تكن تحصل لدى الجميع.<br />AN/19/298/ قد تحدث الأعراض الجانبية التالية مع هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كغيره من الأدوية، أقراص أنجيوتك يمكن أن تسبب آثار جانبية، وإن لم تكن تحصل لدى الجميع.<br />AN/19/298/ قد تحدث الأعراض الجانبية التالية مع هذا الدواء:vتوقف عن تناول أنجيوتك و تحدث إلى طبيبك على الفور، إذا لاحظت أي من الآتي :<br />تورم في الوجه والشفتين واللسان أو الحنجرة التي قد تسبب صعوبة في التنفس أو البلع. □<br />تورم يديك أو قدميك أو الكاحلين. □<br />إذا ظهر لديك طفح جلدي (شرى). □<br />يجب أن تكون على علم بأن المرضى ذوي البشرة السوداء هم في خطر متزايد من هذه الأنواع من ردود الفعل. إذا حدث أي مما سبق، توقف عن تناول أنجيوتيك وتحدث إلى طبيبك<br />على الفور.<br />عند بدء تناول هذا الدواء قد تشعر بضعف أو بالدوار. إذا حدث هذا، فإن الاستلقاء سوف يساعد على الراحة. يحدث ذلك نتيجة لإنخفاض ضغط الدم. وينبغي أن تتحسن كلما كنت<br />مستمر في تناول هذا الدواء. إذا كنت قلق من تناول هذا الدواء، يرجى التحدث إلى طبيبك<br />وتشمل الأعراض الجانبية الأخرى:<br />أعراض جانبية شائعة جداً (قد تؤثر على أكثر من شخص واحد من أصل ۱۰ أشخاص)<br />السعال . □ . عدم وضوح الرؤية □ . الشعور بالدوار، الضعف أو المرض □<br />أعراض جانبية شائعة (قد تؤثر على شخص من أصل ۱۰ أشخاص)<br />الدوار بسبب انخفاض ضغط الدم، التغيرات في إيقاع القلب، سرعة ضربات القلب، الذبحة الصدرية أو ألم في الصدر. □<br />ضيق في التنفس. □ . الصداع، الاكتئاب، والإغماء (إغماء) تغيير في شعور التذوق □<br />إعياء (التعب). □ . الإسهال أو ألم في البطن □<br />طفح جلدي، ردود فعل تحسسية مع تورم في الوجه والشفتين واللسان أو الحلق مع صعوبة في البلع أو التنفس. □<br />مستويات عالية من البوتاسيوم في الدم، وزيادة مستويات الكرياتينين في الدم (وعادة ما يتم الكشف عنه عن طريق التحاليل). □<br />أعراض جانبية غير شائعة (قد تؤثر على ما يصل إلى ۱ من ۱۰۰ شخص)<br />نوبة قلبية (ربما بسبب ضغط الدم المنخفض جداً في بعض المرضى الذين □ ( سرعة أوعدم تساوي في نبضات القلب (خفقان □ . هبوط مفاجيء في الضغط □ . احمرار في الوجه □<br />السكتة الدماغية (بسبب انخفاض ضغط الدم جداً في المرضى الذين يعانون □ .( يعانون من مخاطر عالية، بما في ذلك أولئك الذين يعانون من مشاكل في تدفق الدم في القلب أو الدماغ<br />إحساس يشبه وخز الدبوس أو الإبرة في الجلد. □ . الارتباك، الأرق أو النعاس، والعصبية □ .( فقر الدم (بما في ذلك فقر الدم اللاتنسجي وانحلال الدم □ .( من مخاطر عالية<br />بطء في حركة مرور الغذاء خلال □ . ربو مرتبط مع صعوبة التنفس □ . سيلان الأنف التهاب الحلق و بحة في الصوت □ .( رنين في أذنيك (طنين □ .( دوار ( احساس بالدوران □<br />تقلصات عضلية. □ . تهيج في المعدة، جفاف في الفم، قرحات هضمية □ . الإصابة بالغثيان (قيء)، عسر في الهضم، إمساك، فقدان الشهية □ . الأمعاء، التهاب في البنكرياس<br />الشعور بأنك لست على مايرام بصورة عامة، درجات حرارة □ . فقدان الشعر □ . حكة أو الطفح القراصي □ . التعرق الشديد □ . انخفاض في وظائف الكلى أوحدوث فشل كلوي □<br />كميات قليلة من السكر أو الصوديوم، كميات كبيرة من الدم في □ . كمية بروتين عالية في البول، و يتم اكتشافه عادة عن طريق فحص مخبري □ . ضعف جنسي □ .( عالية (حمى<br />البول(جميعه يتم اكتشافه عن طريق فحص الدم).<br />الأعراض الجانبية النادرة (تؤثر على أقل من شخص واحد من أصل ۱۰۰۰ أشخاص):<br />تغير في قراءات الدم مثل :نقصان في عدد خلايا الدم البيضاء و الحمراء، نقص □ . ظاهرة رينود&#39; حيث تصبح يديك وقدميك باردتان جداً ولونهم أبيض بسبب انخفاض تدفق الدم &#39; □<br />أحلام غير طبيعية ومشاكل في النوم. □ . أمراض المناعة الذاتية □ . تورم الغدد في الرقبة، الإبط أو الفخذ □ . تثبيط نخاع العظم □ . الهيموغلوبين و انخفاض عدد الصفائح الدموية<br />التهاب الخدين □ .( التهاب الرئتين مما يسبب صعوبة في التنفس (الالتهاب الرئوي □ . التهاب في أنفك □ .( تراكم السوائل أو مواد أخرى في الرئتين (كما ترى على الأشعة السينية □<br />متلازمة ستيفنز جونسون&#39; وتقشر الأنسجة المتموتة البشرية السامة (الحالات الجلدية &#39; □ .( طفح جلدي (حمامى عديدة الأشكال □ . حصر في البول □ . واللثة واللسان والشفتين والحلق<br />الخطيرة حيث يكون لديك احمرار وتقرح في بشرتك، قرح أو قروح الخام)، التهاب الجلد التقشري / احمرار الجلد (طفح جلدي شديد مع تساقط أو تقشير الجلد)، فقاع (فقاعات صغيرة<br />مشاكل في الكبد أو المرارة مثل انخفاض وظائف الكبد، التهاب الكبد، اليرقان (اصفرار الجلد أو العينين)، مستويات عالية من إنزيمات الكبد أو □ .( مليئة في السوائل على الجلد<br />تضخم الثدي عند الرجال (التثدي). □ .( البيليروبين (تقاس في اختبار الدم<br />الأعراض الجانبية النادرة جداً (تؤثر على أقل من شخص واحد في ۱۰۰۰۰ شخص):<br />إنتفاخ في أمعائك (الوذمة الوعائية في الأمعاء). □<br />الأعراض الجانبية غير المعروفة (لا يمكن تقدير تكرارها من البيانات المتاحة):<br />الإفراط في إنتاج هرمون المضاد لإدرار البول، والذي يسبب احتباس السوائل، مما يؤدي إلى ضعف، التعب أو الارتباك. □<br />تم الإبلاغ عن أعراض معقدة قد تتضمن بعض أو كل ما يلي: الحمى، والتهاب الأوعية الدموية (التهاب المصلية / التهاب الأوعية الدموية)، وآلام في العضلات (ألم عضلي / □<br />التهاب العضل)، وآلام المفاصل (ألم مفصلي / التهاب المفاصل). قد يحدث طفح جلدي، حساسية للضوء أو مظاهر جلدية أخرى</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا ينبغي استعمال أنجيوتك بعد تاريخ انتهاء الصلاحية الموجود على العلبة وعلى شريط الدواء. □ . لا يحفظ بدرجة حرارة أعلى من ۳۰ &deg;م □ . يحفظ بعيداً عن متناول الأطفال □<br />لا ينبغي التخلص من الأدوية من خلال مياه الصرف الصحي أ المنزلي. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد مطلوبة.<br />سوف تساعد هذه الاجراءات على حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أنجيوتك:<br />۲۰ يحتوي على ٥ ملغم و ۱۰ ملغم و ۲۰ ملغم على التوالي من إنالابريل ماليات. ،۱۰ ، المادة الفعالة هي إنالابريل ماليات. كل قرص من أقراص أنجيوتك ٥ □<br />المكونات الأخرى هي: لاكتوز، نشا الذرة، حمض الستياريك ثلاثي الغليسيريد</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            :
من جهة واحدة . "AN أقراص أنجيوتك ٥ ملغم هي أقراص بيضاء اللون، دائرية، مسطحة، مائلة الحواف، منقوش عليها " 5 □
من جهة واحدة. "AN أقراص أنجيوتك ۱۰ ملغم هي أقراص بيضاء اللون، دائرية، مسطحة، مائلة الحواف، منقوش عليها " 10 □
من جهة واحدة. "AN أقراص أنجيوتك ۲۰ ملغم هي أقراص بيضاء اللون، دائرية، مسطحة، مائلة الحواف، منقوش عليها " 20 □
علب تحتوي على ۳۰ قرص أنجيوتك ٥ المحفوظة في أشرطة. □
علب تحتوي على ۳۰ قرص أنجيوتك ۱۰ المحفوظة في أشرطة. □
علب تحتوي على ۲۰ قرص أنجيوتك ۲۰ المحفوظة في أشرطة. □
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة الاردنية لانتاج الادوية المساهمة العامة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تشرين الثاني 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ANGIOTEC 10 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active Ingredient:

Each tablet contains Enalapril Maleate 10 mg. 

Inactive Ingredients:

Inactive ingredients(s) and amount (s) per unit dose:
Inactive Ingredient (s): (mg / Tab.)
Lactose	98.30 mg
Maize Starch	14.00 mg
Triglyceride Stearic Acid	2.50 mg

  *For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ANGIOTEC 10mg  Tablet :

Circular, flat face Bevelled edge tablet with “AN 10” embossed on one side

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of hypertension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of symptomatic heart failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prevention of symptomatic heart failure in patients with asymptomatic left ventricular dysfunction (ejection fraction &le; 35%). (See Section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Route of administration</strong>: Oral</p><p>The maximum daily dose is 40 mg.</p><p>The absorption of enalapril is not affected by food.</p><p>The dose should be individualised according to patient profile (see Section 4.4) and blood pressure response.</p><p><em><u>Hypertension</u></em></p><p>The initial dose is 5 to maximally 20 mg, depending on the degree of hypertension and the condition of the patient (see below). Enalapril is given once daily. In mild hypertension, the recommended initial dose is 5 to 10 mg. Patients with a strongly activated renin-angiotensin-aldosterone system, (e.g., renovascular hypertension, salt and/or volume depletion, cardiac decompensation, or severe hypertension) may experience an excessive blood pressure fall following the initial dose. A starting dose of 5 mg or lower is recommended in such patients and the initiation of treatment should take place under medical supervision.</p><p>Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with enalapril. A starting dose of 5 mg or lower is recommended in such patients. If possible, diuretic therapy should be discontinued for 2-3 days prior to initiation of therapy with enalapril. Renal function and serum potassium should be monitored<em>.</em></p><p>The usual maintenance dose is 20 mg daily. The maximum maintenance dose is 40 mg daily.</p><p><em><u>Heart failure/Asymptomatic left ventricular dysfunction</u></em></p><p>In the management of symptomatic heart failure, enalapril is used in addition to diuretics and, where appropriate, digitalis or beta-blockers. The initial dose of enalapril in patients with symptomatic heart failure or asymptomatic left ventricular dysfunction is 2.5 mg, and it should be administered under close medical supervision to determine the initial effect on the blood pressure. In the absence of, or after effective management of, symptomatic hypotension following initiation of therapy with enalapril in heart failure, the dose should be increased gradually to the usual maintenance dose of 20 mg, given in a single dose or two divided doses, as tolerated by the patient. This dose titration is recommended to be performed over a 2 to 4 week period. The maximum dose is 40 mg daily given in two divided doses.</p><p><em>Suggested dosage titration of enalapril in patients with heart failure/asymptomatic left ventricular dysfunction</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Week </strong></p></td><td style="vertical-align:top"><p><strong>Dose mg/day </strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 1</p></td><td style="vertical-align:top"><p><strong>Days 1 to 3:</strong> 2.5 mg/day* in a single dose</p><p><strong>Days 4 to 7:</strong> 5 mg/day in two divided doses</p></td></tr><tr><td style="vertical-align:top"><p>Week 2</p></td><td style="vertical-align:top"><p>10 mg/day in a single dose or in two divided doses</p></td></tr><tr><td style="vertical-align:top"><p>Weeks 3 and 4</p></td><td style="vertical-align:top"><p>20 mg/day in a single dose or in two divided doses</p></td></tr></tbody></table><p>*Special precautions should be followed in patients with impaired renal function or taking diuretics (See Section 4.4).</p><p>Blood pressure and renal function should be monitored closely both before and after starting treatment with enalapril (see Section 4.4) because hypotension and (more rarely) consequent renal failure have been reported. In patients treated with diuretics, the dose should be reduced if possible before beginning treatment with enalapril. The appearance of hypotension after the initial dose of enalapril does not imply that hypotension will recur during chronic therapy with enalapril and does not preclude continued use of the drug. Serum potassium and renal function also should be monitored.</p><p><em><u>Dosage in renal insufficiency</u></em></p><p>Generally, the intervals between the administration of enalapril should be prolonged and/or the dosage reduced.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance (CrCL) mL/min</strong></p></td><td style="vertical-align:top"><p><strong>Initial dose mg/day</strong></p></td></tr><tr><td style="vertical-align:top"><p>30&lt;CrCL&lt;80 ml/min.</p></td><td style="vertical-align:top"><p>5 - 10 mg</p></td></tr><tr><td style="vertical-align:top"><p>10&lt;CrCL<!--[if gte vml 1]><v:shapetype id="_x0000_t75"
   coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
   filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" alt="LESS-THAN OR EQUAL TO (8804)"
   style='width:9pt;height:9pt'>
   <v:imagedata src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif"
    o:href="http://renderer.medicines.org.uk/DisplayImage.ashx?documentID=26169&amp;key=SPC.26169.1_FILES/IMAGE001.GIF"/>
  </v:shape><![endif]--><img width="12" height="12" alt="LESS-THAN OR EQUAL TO (8804)" src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" />30 ml/min.</p></td><td style="vertical-align:top"><p>2.5 mg</p></td></tr><tr><td style="vertical-align:top"><p>CrCL<!--[if gte vml 1]><v:shape id="_x0000_i1026" type="#_x0000_t75"
   alt="LESS-THAN OR EQUAL TO (8804)" style='width:9pt;height:9pt'>
   <v:imagedata src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif"
    o:href="http://renderer.medicines.org.uk/DisplayImage.ashx?documentID=26169&amp;key=SPC.26169.1_FILES/IMAGE001.GIF"/>
  </v:shape><![endif]--><img width="12" height="12" alt="LESS-THAN OR EQUAL TO (8804)" src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" />10 ml/min.</p></td><td style="vertical-align:top"><p>2.5 mg on dialysis days*</p></td></tr></tbody></table><p>* See Section 4.4 Haemodialysis Patients.</p><p>Enalaprilat is dialysable. Dosage on non-dialysis days should be adjusted depending on the blood pressure response.</p><p><u>Use in elderly </u></p><p>The dose should be in line with the renal function of the elderly patient (see Section 4.4, Renal function impairment).</p><p><u>Use in paediatrics </u></p><p>There is limited clinical trial experience of the use of enalapril in hypertensive paediatric patients (see Section 4.4, Section 5.1 and Section 5.2).</p><p>For patients who can swallow tablets, the dose should be individualised according to patient profile and blood pressure response. The recommended initial dose is 2.5 mg in patients 20 to &lt;50 kg and 5 mg in patients <!--[if gte vml 1]><v:shape id="_x0000_i1027" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
 style='width:9pt;height:9pt'>
 <v:imagedata src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image002.gif"
  o:href="http://renderer.medicines.org.uk/DisplayImage.ashx?documentID=26169&amp;key=SPC.26169.1_FILES/IMAGE002.GIF"/>
</v:shape><![endif]--><img width="12" height="12" alt="GREATER-THAN OR EQUAL TO (8805)" src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image002.gif" />50 kg. Enalapril is given once daily. The dosage should be adjusted according to the needs of the patient to a maximum of 20 mg daily in patients 20 to &lt;50 kg and 40 mg in patients <!--[if gte vml 1]><v:shape id="_x0000_i1028" type="#_x0000_t75"
 alt="GREATER-THAN OR EQUAL TO (8805)" style='width:9pt;height:9pt'>
 <v:imagedata src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image002.gif"
  o:href="http://renderer.medicines.org.uk/DisplayImage.ashx?documentID=26169&amp;key=SPC.26169.1_FILES/IMAGE002.GIF"/>
</v:shape><![endif]--><img width="12" height="12" alt="GREATER-THAN OR EQUAL TO (8805)" src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image002.gif" />50 kg (see Section 4.4).</p><p>Enalapril is not recommended in neonates and in paediatric patients with glomerular filtration rate &lt;30 ml/min/1.73 m<sup>2</sup>, as no data are available</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to enalapril, to any of the excipients or any other ACE inhibitor 
• History of angioedema associated with previous ACE-inhibitor therapy 
• Hereditary or idiopathic angioedema 
• Second and third trimesters of pregnancy (see Section 4.4 and 4.6). 
• Sever hepatic impairment

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Symptomatic hypotension</u></p><p>Symptomatic hypotension is rarely seen in uncomplicated hypertensive patients. In hypertensive patients receiving enalapril, symptomatic hypotension is more likely to occur if the patient has been volume depleted, e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea or vomiting (see Section 4.5 and Section 4.8). In patients with heart failure, with or without associated renal insufficiency, symptomatic hypotension has been observed. This is most likely to occur in those patients with more severe degrees of heart failure, as reflected by the use of high doses of loop diuretics, hyponatraemia or functional renal impairment. In these patients, therapy should be started under medical supervision and the patients should be followed closely whenever the dose of enalapril and/or diuretic is adjusted. Similar considerations may apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.</p><p>If hypotension occurs, the patient should be placed in the supine position and, if necessary, should receive an intravenous infusion of normal saline. A transient hypotensive response is not a contra-indication to further doses, which can be given usually without difficulty once the blood pressure has increased after volume expansion.</p><p>In some patients with heart failure who have normal or low blood pressure, additional lowering of systemic blood pressure may occur with enalapril. This effect is anticipated, and usually is not a reason to discontinue treatment. If hypotension becomes symptomatic, a reduction of dose and/or discontinuation of the diuretic and/or enalapril may be necessary.</p><p><u>Aortic or mitral valve stenosis/hypertrophic cardiomyopathy </u></p><p>As with all vasodilators, ACE inhibitors should be given with caution in patients with left ventricular valvular and outflow tract obstruction and avoided in cases of cardiogenic shock and haemodynamically significant obstruction.</p><p><u>Renal function impairment </u></p><p>In cases of renal impairment (creatinine clearance &lt;80 ml/min) the initial enalapril dosage should be adjusted according to the patient&#39;s creatinine clearance (see Section 4.2) and then as a function of the patient&#39;s response to treatment. Routine monitoring of potassium and creatinine are part of normal medical practice for these patients.</p><p>Renal failure has been reported in association with enalapril and has been mainly in patients with severe heart failure or underlying renal disease, including renal artery stenosis. If recognised promptly and treated appropriately, renal failure when associated with therapy with enalapril is usually reversible.</p><p>Some hypertensive patients, with no apparent pre-existing renal disease have developed increases in blood urea and creatinine when enalapril has been given concurrently with a diuretic. Dosage reduction of enalapril and/or discontinuation of the diuretic may be required. This situation should raise the possibility of underlying renal artery stenosis (see Section 4.4).</p><p><u>Renovascular hypertension </u></p><p>There is an increased risk of hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with ACE inhibitors.</p><p>Loss of renal function may occur with only mild changes in serum creatinine. In these patients, therapy should be initiated under close medical supervision with low doses, careful titration, and monitoring of renal function.</p><p><u>Kidney transplantation</u></p><p>There is no experience regarding the administration of enalapril in patients with a recent kidney transplantation. Treatment with enalapril is therefore not recommended.</p><p><u>Hepatic failure </u></p><p>Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.</p><p><u>Neutropenia/Agranulocytosis </u></p><p>Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors. In patients with normal renal function and no other complicating factors, neutropenia occurs rarely. Enalapril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function. Some of these patients developed serious infections which in a few instances did not respond to intensive antibiotic therapy. If enalapril is used in such patients, periodic monitoring of white blood cell counts is advised and patients should be instructed to report any sign of infection.</p><p><u>Hypersensitivity/Angioneurotic oedema </u></p><p>Angioneurotic oedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors, including enalapril. This may occur at any time during treatment. In such cases, enalapril should be discontinued promptly and appropriate monitoring should be instituted to ensure complete resolution of symptoms prior to dismissing the patient. Even in those instances where swelling of the tongue only is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient.</p><p>Very rarely fatalities have been reported due to angioedema associated with laryngeal oedema or tongue oedema. Patients with involvement of the tongue, glottis or larynx are likely to experience airway obstruction, especially those with a history of airway surgery. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, which may include subcutaneous adrenaline (epinephrine) solution 1:1000 (0.3 ml to 0.5 ml) and/or measures to ensure a patent airway, should be administered promptly.</p><p>Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks.</p><p>Patients with a history of angioedema unrelated to ACE-inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (Also see Section 4.3).</p><p><u>Anaphylactoid reactions during hymenoptera desensitisation </u></p><p>Rarely, patients receiving ACE inhibitors during desensitisation with hymenoptera venom have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE-inhibitor therapy prior to each desensitisation.</p><p><u>Anaphylactoid reactions during LDL Apheresis </u></p><p>Rarely, patients receiving ACE inhibitors during low density lipoprotein LDL apheresis with dextran sulfate have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE-inhibitor therapy prior to each apheresis.</p><p><u>Haemodialysis patients </u></p><p>Anaphylactoid reactions have been reported in patients dialysed with high-flux membranes (e.g. AN 69) and treated concomitantly with an ACE inhibitor. In these patients, consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.</p><p><u>Diabetic patients </u></p><p>In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should be closely monitored during the first month of treatment with an ACE inhibitor (See Section 4.5,)</p><p><u>Cough </u></p><p>Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.</p><p><u>Surgery/Anaesthesia </u></p><p>In patients undergoing major surgery or during anaesthesia with agents that produce hypotension, enalapril blocks angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.</p><p><u>Hyperkalaemia </u></p><p>Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including enalapril. Risk factors for the development of hyperkalaemia include those with renal insufficiency, worsening of renal function, age (&gt;70 years), diabetes mellitus, inter-current events, in particular dehydration, acute cardiac decompensation, metabolic acidosis and concomitant use of potassium-sparing diuretics (eg. spironolactone, eplerenone, triamterene or amiloride),, potassium supplements or potassium-containing salt substitutes; or those patients taking other drugs associated with increases in serum potassium, (e.g. heparin). Hyperkalemia can cause serious, sometimes fatal arrhythmias. If concomitant use of enalapril and any of the above mentioned agents is deemed appropriate, they should be used with caution and with frequent monitoring of serum potassium (see section 4.5).</p><p><u>Lithium </u></p><p>The combination of lithium and enalapril is generally not recommended (see Section 4.5).</p><p><u>Lactose </u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine</p><p><u>Paediatric use </u></p><p>There is limited efficacy and safety experience in hypertensive children &gt;6 years old, but no experience in other indications. Limited pharmacokinetic data are available in children above 2 months of age (Also see Section 4.2, Section 5.1 and Section 5.2). Enalapril is not recommended in children in other indications than hypertension.</p><p>Enalapril is not recommended in neonates and in paediatric patients with glomerular filtration rate &lt;30 ml/min/1.73 m<sup>2</sup>, as no data are available. (See Section 4.2)</p><p><u>Ethnic differences </u></p><p>As with other angiotensin-converting enzyme inhibitors, enalapril is apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.</p><p><u>Pregnancy</u></p><p>ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started (see Sections 4.3 and 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>v</p><p><u>Potassium-sparing diuretics or potassium supplements </u></p><p>ACE inhibitors attenuate diuretic-induced potassium loss. Potassium-sparing diuretics (e.g. spironolactone, triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. If concomitant use is indicated because of demonstrated hypokalaemia they should be used with caution and with frequent monitoring of serum potassium (see Section 4.4).</p><p><u>Diuretics (thiazide or loop diuretics) </u></p><p>Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with enalapril (see Section 4.4). The hypotensive effects can be reduced by discontinuation of the diuretic, by increasing volume or salt intake or by initiating therapy with a low dose of enalapril.</p><p><u>Other antihypertensive agents </u></p><p>Concomitant use of these agents may increase the hypotensive effects of enalapril. Concomitant use with nitroglycerine and other nitrates, or other vasodilators, may further reduce blood pressure.</p><p><u>Lithium </u></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide diuretics may further increase lithium levels and enhance the risk of lithium toxicity with ACE inhibitors. Use of enalapril with lithium is not recommended, but if the combination proves necessary, careful monitoring of serum lithium levels should be performed (see Section 4.4).</p><p><u>Tricyclic antidepressants/Antipsychotics/Anaesthetics/Narcotics </u></p><p>Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and antipsychotics with ACE inhibitors may result in further reduction of blood pressure (see Section 4.4).</p><p><u>Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) </u></p><p>Chronic administration of NSAIDs may reduce the antihypertensive effect of an ACE inhibitor.</p><p>NSAIDs including COX-2 inhibitors) and ACE inhibitors exert an additive effect on the increase in serum potassium, and may result in a deterioration of renal function. These effects are usually reversible. Rarely, acute renal failure may occur, especially in patients with compromised renal function such as the elderly or patients who are volume-depleted including those on diuretic therapy.</p><p><u>Sympathomimetics </u></p><p>Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.</p><p><u>Antidiabetics </u></p><p>Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment.</p><p><u>Dual Blockade of the Renin-Angiotensin System (RAS):</u></p><p>Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function, and electrolytes in patient on enalapril and other agents that affect the RAS.</p><p><u>Aliskiren:</u></p><p>Do not co-administer aliskiren with enalapril in patients with diabetes. Avoid use of aliskiren with enalapril in patient with renal impairment (GFR&lt;60 ml/min).</p><p>&nbsp;</p><p><u>Alcohol </u></p><p>Alcohol enhances the hypotensive effect of ACE inhibitors.</p><p><u>Acetyl salicylic acid, thrombolytics and &beta; - blockers</u></p><p>Enalapril can be safely administered concomitantly with acetyl salicylic acid (at cardiologic doses), thrombolytics and &beta;-blockers.</p><p><u>Gold</u></p><p>Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including enalapril.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>USE IN PREGNANCY</strong></p><p><strong>When used in pregnancy during the second and third trimesters, drugs that act directly on the rennin-angiotensin system can cause injury and even death to the developing fetus. </strong>When pregnancy is detected, <strong>ANGIOTEC</strong> should be discontinued as soon as possible.</p><p>The use of ACE-inhibitors is not recommended during the first trimester of pregnancy (see Section 4.4). The use of ACE inhibitors is contraindicated during the second and third trimesters (see sections 4.3 and 4.4).</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>ACE inhibitor therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3). Should exposure to ACE inhibitor have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see also section 4.3 and 4.4).</p><p><u>Lactation</u></p><p>Limited pharmacokinetic data demonstrated very low concentrations in breast milk (see section 5.2). Although these concentrations seem to be clinically irrelevant, the use of enalapril in breastfeeding is not recommended for preterm infants and for the first few weeks after delivery, because of the hypothetical risk of cardiovascular and renal effects and because there is not enough clinical experience. In the case of an older infant, the use of enalapril in a breastfeeding mother may be considered if the treatment is necessary for the mother and the child is observed for any adverse effect.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects reported for enalapril include:</p><p>Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p><u>Blood and the lymphatic system disorders: </u></p><p>Uncommon: anaemia (including aplastic and haemolytic).</p><p>Rare: neutropenia, decreases in haemoglobin, decreases in haematocrit, thrombocytopenia, agranulocytosis, bone marrow depression, pancytopenia, lymphadenopathy, autoimmune diseases.</p><p><u>Metabolism and nutrition disorders: </u></p><p>Uncommon: hypoglycaemia (see section 4.4, Diabetic patients).</p><p><u>Nervous system and psychiatric disorders: </u></p><p>Common: depression, headache.</p><p>Uncommon: confusion, somnolence, insomnia, nervousness, paraesthesia, vertigo</p><p>Rare: dream abnormality, sleep disorders.</p><p><u>Eye disorders: </u></p><p>Very common: blurred vision.</p><p><u>Cardiac and vascular disorders: </u></p><p>Very common: dizziness.</p><p>Common: hypotension (including orthostatic hypotension), syncope, chest pain, rhythm disturbances, angina pectoris, tachycardia</p><p>Uncommon: orthostatic hypotension, palpitations, myocardial infarction or cerebrovascular accident*, possibly secondary to excessive hypotension in high risk patients (see section 4.4).</p><p>Rare: Raynaud&#39;s phenomenon.</p><p><u>* Incidence rates were comparable to those in the placebo and active control groups in the clinical trials.</u></p><p><u>Respiratory, thoracic and mediastinal disorders: </u></p><p>Very common: cough.</p><p>Common: dyspnoea.</p><p>Uncommon: bronchospasm/asthma, rhinorrhoea, sore throat and hoarseness.</p><p>Rare: allergic alveolitis/eosinophilic pneumonia, pulmonary infiltrates, rhinitis.</p><p><u>Gastro-intestinal disorders: </u></p><p>Very common: nausea.</p><p>Common: diarrhoea, abdominal pain, taste alteration.</p><p>Uncommon: ileus, pancreatitis, peptic ulcer, vomiting, dyspepsia, constipation, anorexia, gastric irritations, dry mouth.</p><p>Rare: stomatitis/aphthous ulcerations, glossitis.</p><p>Very rare: intestinal angioedema</p><p><u>Hepatobiliary disorders: </u></p><p>Rare : hepatic failure, hepatitis &ndash; either hepatocellular or cholestatic, hepatitis including necrosis, cholestasis (including jaundice).</p><p><u>Skin and subcutaneous tissue disorders: </u></p><p>Common: hypersensitivity/angioneurotic oedema: angioneurotic oedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported (see Section 4.4), rash.</p><p>Uncommon: diaphoresis, pruritus, urticaria, alopecia.</p><p>Rare: Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, pemphigus, erythema multiforme, erythroderma.</p><p>A symptom complex has been reported which may include some or all of the following: fever, serositis, vasculitis, myalgia/myositis, arthralgia/arthritis, a positive ANA, elevated ESR, eosinophilia, and leukocytosis. Rash, photosensitivity or other dermatologic manifestations may occur.</p><p><u>Renal and urinary disorders: </u></p><p>Uncommon: renal failure, renal dysfunction, proteinuria.</p><p>Rare: oliguria.</p><p><u>Reproductive system and breast disorders: </u></p><p>Uncommon: impotence.</p><p>Rare: gynecomastia.</p><p><u>General disorders and administration site conditions</u><em>:</em></p><p>Very common: asthenia.</p><p>Common: fatigue.</p><p>Uncommon: muscle cramps, flushing, tinnitus, malaise, fever.</p><p><u>Investigations: </u></p><p>Common: hyperkalaemia, increases in serum creatinine.</p><p>Uncommon: increases in blood urea, hyponatraemia.</p><p>Rare: elevations of liver enzymes, elevations of serum bilirubin.</p><p><u>Endocrine disorders</u></p><p>Not known: syndrome of inappropriate antidiuretic hormone secretion (SIADH)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Limited data are available for overdosage in humans. The most prominent features of overdosage reported to date are marked hypotension, beginning some six hours after ingestion of tablets, concomitant with blockade of the renin-angiotensin system, and stupor. Symptoms associated with overdosage of ACE inhibitors may include circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety, and cough. Serum enalaprilat levels 100- and 200-fold higher than usually seen after therapeutic doses have been reported after ingestion of 300 mg and 440 mg of enalapril, respectively.</p><p>The recommended treatment of overdosage is intravenous infusion of normal saline solution. If hypotension occurs, the patient should be placed in the shock position. If available, treatment with angiotensin II infusion and/or intravenous catecholamines may also be considered. If ingestion is recent, take measures aimed at eliminating enalapril maleate (e.g. emesis, gastric lavage, administration of absorbents, and sodium sulfate). Enalaprilat may be removed from the general circulation by haemodialysis (See Section 4.4, <em>Haemodialysis patients</em>). Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations should be monitored continuously.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin-converting enzyme inhibitors, ATC Code: C09A A02</p><p>Enalapril maleate is the maleate salt of enalapril, a derivative of two amino-acids, L-alanine and L-proline. Angiotensin converting enzyme (ACE) is a peptidyl dipeptidase which catalyses the conversion of angiotensin I to the pressor substance angiotensin II. After absorption, enalapril is hydrolysed to enalaprilat, which inhibits ACE. Inhibition of ACE results in decreased plasma angiotensin II, which leads to increased plasma renin activity (due to removal of negative feedback of renin release), and decreased aldosterone secretion.</p><p>ACE is identical to kininase II. Thus enalapril may also block the degradation of bradykinin, a potent vasodepressor peptide. However, the role that this plays in the therapeutic effects of enalapril remains to be elucidated.</p><p>While the mechanism through which enalapril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, enalapril is antihypertensive even in patients with low-renin hypertension.</p><p>Administration of enalapril to patients with hypertension results in a reduction of both supine and standing blood pressure without a significant increase in heart rate.</p><p>Symptomatic postural hypotension is infrequent. In some patients the development of optimal blood pressure reduction may require several weeks of therapy. Abrupt withdrawal of enalapril has not been associated with rapid increase in blood pressure.</p><p>Effective inhibition of ACE activity usually occurs 2 to 4 hours after oral administration of an individual dose of enalapril. Onset of antihypertensive activity was usually seen at one hour, with peak reduction of blood pressure achieved by 4 to 6 hours after administration. The duration of effect is dose-related. However, at recommended doses, antihypertensive and haemodynamic effects have been shown to be maintained for at least 24 hours.</p><p>In haemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with an increase in cardiac output and little or no change in heart rate. Following administration of enalapril there was an increase in renal blood flow; glomerular filtration rate was unchanged. There was no evidence of sodium or water retention. However, in patients with low pre-treatment glomerular filtration rates, the rates were usually increased.</p><p>In short-term clinical studies in diabetic and non-diabetic patients with renal disease, decreases in albuminuria and urinary excretion of IgG and total urinary protein were seen after the administration of enalapril.</p><p>When given together with thiazide-type diuretics, the blood pressure-lowering effects of enalapril are at least additive. Enalapril may reduce or prevent the development of thiazide-induced hypokalaemia.</p><p>In patients with heart failure on therapy with digitalis and diuretics, treatment with oral or injection enalapril was associated with decreases in peripheral resistance and blood pressure. Cardiac output increased, while heart rate (usually elevated in patients with heart failure) decreased. Pulmonary capillary wedge pressure was also reduced. Exercise tolerance and severity of heart failure, as measured by New York Heart Association criteria, improved. These actions continued during chronic therapy.</p><p>In patients with mild to moderate heart failure, enalapril retarded progressive cardiac dilatation/enlargement and failure, as evidenced by reduced left ventricular end diastolic and systolic volumes and improved ejection fraction.</p><p>A multicentre, randomised, double-blind, placebo-controlled trial (SOLVD Prevention trial) examined a population with asymptomatic left ventricular dysfunction (LVEF &lt;35%). 4228 patients were randomised to receive either placebo (n=2117) or enalapril (n=2111). In the placebo group, 818 patients had heart failure or died (38.6%) as compared with 630 in the enalapril group (29.8%) (risk reduction: 29%; 95% CI; 21 - 36%; p &lt;0.001). 518 patients in the placebo group (24.5%) and 434 in the enalapril group (20.6%) died or were hospitalised for new or worsening heart failure (risk reduction 20%; 95% CI; 9-30%; p &lt;0.001).</p><p>A multicentre, randomised, double-blind, placebo-controlled trial (SOLVD treatment trial) examined a population with symptomatic congestive heart failure due to systolic dysfunction (ejection fraction &lt;35%). 2569 patients receiving conventional treatment for heart failure were randomly assigned to receive either placebo (n=1284) or enalapril (n=1285). There were 510 deaths in the placebo group (39.7%) as compared with 452 in the enalapril group (35.2%) (reduction in risk, 16%; 95% CI, 5 - 26%; p=0.0036). There were 461 cardiovascular deaths in the placebo group as compared with 399 in the enalapril group (risk reduction 18%, 95% CI, 6 - 28%, p &lt;0.002), mainly due to a decrease of deaths due to progressive heart failure (251 in the placebo group vs 209 in the enalapril group, risk reduction 22%, 95% CI, 6 - 35%). Fewer patients died or were hospitalised for worsening heart failure (736 in the placebo group and 613 in the enalapril group; risk reduction, 26%; 95% CI, 18 - 34%; p&lt;0.0001). Overall in SOLVD study, in patients with left ventricular dysfunction, enalapril reduced the risk of myocardial infarction by 23% (95% CI, 11 &ndash; 34%; p&lt;0.001) and reduced the risk of hospitalisation for unstable angina pectoris by 20% (95% CI, 9 &ndash; 29%; p &lt;0.001).</p><p>There is limited experience of the use in hypertensive paediatric patients &gt;6 years. In a clinical study involving 110 hypertensive paediatric patients 6 to 16 years of age with a body weight <!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
 style='width:9pt;height:9pt'>
 <v:imagedata src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif"
  o:href="http://renderer.medicines.org.uk/DisplayImage.ashx?documentID=26169&amp;key=SPC.26169.1_FILES/IMAGE002.GIF"/>
</v:shape><![endif]--><img width="12" height="12" alt="GREATER-THAN OR EQUAL TO (8805)" src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" />20 kg and a glomerular filtration rate &gt;30 ml/min/1.73 m<sup>2</sup>, patients who weighed &lt;50 kg received either 0.625, 2.5 or 20 mg of enalapril daily and patients who weighed <!--[if gte vml 1]><v:shape id="_x0000_i1026" type="#_x0000_t75"
 alt="GREATER-THAN OR EQUAL TO (8805)" style='width:9pt;height:9pt'>
 <v:imagedata src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif"
  o:href="http://renderer.medicines.org.uk/DisplayImage.ashx?documentID=26169&amp;key=SPC.26169.1_FILES/IMAGE002.GIF"/>
</v:shape><![endif]--><img width="12" height="12" alt="GREATER-THAN OR EQUAL TO (8805)" src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" />50 kg received either 1.25, 5 or 40 mg of enalapril daily. Enalapril administration, once daily, lowered trough blood pressure in a dose-dependent manner. The dose-dependent antihypertensive efficacy of enalapril was consistent across all subgroups (age, Tanner stage, gender, race). However, the lowest doses studied, 0.625 mg and 1.25 mg, corresponding to an average of 0.02 mg/kg once daily, did not appear to offer consistent antihypertensive efficacy. The maximum dose studied was 0.58 mg/kg (up to 40 mg) once daily. The adverse experience profile for paediatric patients is not different from that seen in adult patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral enalapril is rapidly absorbed, with peak serum concentrations of enalapril occurring within one hour. Based on urinary recovery, the extent of absorption of enalapril from oral enalapril tablet is approximately 60%. The absorption of oral enalapril is not influenced by the presence of food in the gastro-intestinal tract.</p><p>Following absorption, oral enalapril is rapidly and extensively hydrolysed to enalaprilat, a potent angiotensin-converting enzyme inhibitor. Peak serum concentrations of enalaprilat occur about 4 hours after an oral dose of enalapril tablet. The effective half-life for accumulation of enalaprilat following multiple doses of oral enalapril is 11 hours. In subjects with normal renal function, steady-state serum concentrations of enalaprilat were reached after 4 days of treatment.</p><p>Over the range of concentrations which are therapeutically relevant, enalaprilat binding to human plasma proteins does not exceed 60%.</p><p>Except for conversion to enalaprilat, there is no evidence for significant metabolism of enalapril.</p><p>Excretion of enalaprilat is primarily renal. The principal components in urine are enalaprilat, accounting for about 40% of the dose, and intact enalapril (about 20%).</p><p><u>Renal impairment </u></p><p>The exposure of enalapril and enalaprilat is increased in patients with renal insufficiency. In patients with mild to moderate renal insufficiency (creatinine clearance 40-60 ml/min) steady state AUC of enalaprilat was approximately two-fold higher than in patients with normal renal function after administration of 5 mg once daily. In severe renal impairment (creatinine clearance <!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" alt="LESS-THAN OR EQUAL TO (8804)"
 style='width:9pt;height:9pt'>
 <v:imagedata src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif"
  o:href="http://renderer.medicines.org.uk/DisplayImage.ashx?documentID=26169&amp;key=SPC.26169.1_FILES/IMAGE001.GIF"/>
</v:shape><![endif]--><img width="12" height="12" alt="LESS-THAN OR EQUAL TO (8804)" src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" />30 ml/min), AUC was increased approximately 8-fold. The effective half-life of enalaprilat following multiple doses of enalapril maleate is prolonged at this level of renal insufficiency and time to steady state is delayed (see Section 4.2). Enalaprilat may be removed from the general circulation by haemodialysis. The dialysis clearance is 62 ml/min.</p><p><u>Children and adolescents </u></p><p>A multiple dose pharmacokinetic study was conducted in 40 hypertensive male and female paediatric patients aged 2 months to <!--[if gte vml 1]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" alt="LESS-THAN OR EQUAL TO (8804)"
 style='width:9pt;height:9pt'>
 <v:imagedata src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif"
  o:href="http://renderer.medicines.org.uk/DisplayImage.ashx?documentID=26169&amp;key=SPC.26169.1_FILES/IMAGE001.GIF"/>
</v:shape><![endif]--><img width="12" height="12" alt="LESS-THAN OR EQUAL TO (8804)" src="file:///C:\Users\ssalayta\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" />16 years following daily oral administration of 0.07 to 0.14 mg/kg enalapril maleate. There were no major differences in the pharmacokinetics of enalaprilat in children compared with historic data in adults. The data indicate an increase in AUC (normalised to dose per body weight) with increased age; however, an increase in AUC is not observed when data are normalised by body surface area. At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours.</p><p><u>Lactation </u></p><p>After a single 20mg oral dose in five postpartum women, the average peak enalapril milk level was 1.7&micro;g/L (range 0.54 to 5.9&micro;g/L) at 4 to 6 hours after the dose. The average peak enalaprilat level was 1.7&micro;g/L (range 1.2 to 2.3&micro;g/L); peaks occurred at various times over the 24-hour period. Using the peak milk level data, the estimated maximum intake of an exclusively breastfed infant would be about 0.16% of the maternal weight-adjusted dosage. A woman who has been taking oral enalapril 10mg daily for 11 months had peak enalapril milk levels of 2&micro;g/L 4 hours after dose and peak enalaprilat levels of 0.75&micro;g/L about 9 hours after the dose. The total amount of enalapril and enalaprilat measured in milk during the 24 hours period was 1.44&micro;g/L and 0.63&micro;g/L of milk respectively. Enalaprilat milk levels were undetectable (&lt;0.2&micro;g/L) 4 hours after a single dose of enalapril 5mg in one mother and 10mg in two mothers; enalapril levels were not determined.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. Reproductive toxicity studies suggest that enalapril has no effects on fertility and reproductive performance in rats, and is not teratogenic. In a study in which female rats were dosed prior to mating through gestation, an increased incidence of rat pup deaths occurred during lactation. The compound has been shown to cross the placenta and is secreted in milk. Angiotensin-converting enzyme inhibitors, as a class, have been shown to be foetotoxic (causing injury and/or death to the foetus) when given in the second or third trimester.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose</p><p>Maize Starch</p><p>Triglyceride Stearic Acid</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Three  years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ANGIOTEC 10 mg Tablets are packed in boxes of 30 Tablets blistered in aluminium foil</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Jordanian Pharmaceutical Manufacturing Co. Ltd.
PO Box 151
Um Al-Amad 16197
Jordan

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>